Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma.

Date
2020
Author
Yagci, Munci
BEKSAÇ, MERAL
Aydin, Yildiz
GÖKER, HAKAN
Turgut, Mehmet
Cagirgan, Seckin
Tuglular, Tulin
VURAL, FİLİZ
ALACACIOĞLU, İNCİ
Aytan, Pelin
Goksoy, Hasan Sami
Gulbas, Zafer
Gunes, Ahmet Kursad
GÜRKAN, EMEL
Hacioglu, Sibel Kabukcu
Karti, Suleyman Sami
KAYNAR, LEYLAGÜL
Ozdogu, Hakan
PAYDAŞ, SEMRA
Solmaz, Soner
SÖNMEZ, MEHMET
Tekgunduz, Emre
YILDIRIM, Rahşan
İLHAN, OSMAN
Besisik, Sevgi
Metadata
Show full item record
Abstract
The present study investigated the efficacy and safety profile of daratumumab monotherapy in 42 patients with relapsed refractory multiple myeloma through a Turkish early access program. The current findings have confirmed the efficacy of daratumumab monotherapy in heavily pretreated patients with refractory multiple myeloma because of the deep and durable responses and favorable safety and tolerability profile.
URI
http://hdl.handle.net/20.500.12627/3887
https://doi.org/10.1016/j.clml.2020.02.017
Collections